Daniel Bergé
Autonomous University of Barcelona
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Daniel Bergé.
Acta Psychiatrica Scandinavica | 2011
Daniel Bergé; Susanna Carmona; Mariana Rovira; Antoni Bulbena; P. Salgado; Oscar Vilarroya
Bergé D, Carmona S, Rovira M, Bulbena A, Salgado P, Vilarroya O. Gray matter volume deficits and correlation with insight and negative symptoms in first‐psychotic‐episode subjects.
Progress in Neuro-psychopharmacology & Biological Psychiatry | 2009
Marc Guitart-Masip; Juan C. Pascual; Susanna Carmona; Elseline Hoekzema; Daniel Bergé; Víctor Pérez; Joaquim Soler; Joan Carles Soliva; Mariana Rovira; Antoni Bulbena; Oscar Vilarroya
A common approach to study neuronal aspects of emotional reactivity of borderline personality disorder (BPD) is to study the brain response to emotional faces with functional magnetic resonance imaging (fMRI). 10 BPD patients and 10 matched controls were submitted to an emotional discrimination task in which subjects had to identify an emotional face from a neutral face while fMRI data was acquired. BPD patients made more mistakes than controls in the discrimination task when negative faces were involved. The emotional discrimination task activated brain areas that are known to participate in processing of emotional faces (fusiform gyrus, insula and amygdala) regardless of the psychiatric condition. Additionally, BPD showed higher activation than controls in the middle and inferior temporal cortical areas, brain areas that participate in the processing of face features that carry emotional value. Furthermore, activity at this site correlated with impulsivity score in the Zuckerman-Kuhlman Personality Questionnaire. Our findings may be related to cognitive impairment that may be characteristic of the disorder.
Comprehensive Psychiatry | 2014
Anna Mané; Clemente Garcia-Rizo; María Paz García-Portilla; Daniel Bergé; Gisela Sugranyes; Leticia García-Álvarez; Miquel Bernardo; Julio Bobes; Emilio Fernandez-Egea
Negative symptoms prevalent in schizophrenia are associated with poor outcome. Developing new instruments to identify new treatments was highlighted at the NIMH-MATRICS Consensus Development Conference on Negative Symptoms. The new Brief Negative Symptoms scale (BNSS) demonstrated strong psychometric properties, but there is a need for validating it in non-English languages. A multi-center study was conducted to validate the Spanish version of the BNSS (BNSS-Sp) in 20 schizophrenia patients, following the original BNSS validation methodology. We found strong inter-rater, test-retest and internal consistency properties (for the total BNSS-Sp, intraclass correlation coefficient=0.97, Pearsons correlation coefficient r=0.95 (p<0.001), Cronbachs alpha=0.98).
Psychiatric Services | 2015
Daniel Bergé; Anna Mané; Purificación Salgado; Romina Cortizo; Carolina Garnier; Laura Gomez; Cristobal Diez-Aja; Antoni Bulbena; Víctor Pérez
OBJECTIVE First-episode psychosis has an annual incidence rate of 24.6 to 40.9 per 100,000 population, and most individuals develop chronic disorders, such as schizophrenia or affective psychosis. The first two to five years are thought to be key determinants of long-term functional and clinical prognosis. This study aimed to determine the two-year course of illness in first-episode psychosis, including diagnosis, relapse, and functioning and factors related to these variables. METHODS A total of 140 patients who experienced a first episode of psychosis were recruited and evaluated between 2008 and 2012 in a first-episode psychosis program in Barcelona, Spain. Regression models were used to determine factors predicting relapse and functioning. RESULTS A general trend was noted toward improved functioning and less severe psychotic symptoms. However, after two years, one-third of the patients had a diagnosis of schizophrenia and more than 40% had a diagnosis of affective psychosis. Rates of relapse were 31% after one year and 43% at two years. Cannabis use after illness onset and poor insight were the best predictors of relapse. Being male and severity of negative symptoms at baseline predicted worse functioning at two years. CONCLUSIONS Patients with first-episode psychosis were found to have high relapse rates during the first years after illness onset. Further studies evaluating treatment strategies focused on reducing cannabis use and improving insight in first-episode psychosis should be encouraged.
Schizophrenia Research | 2015
María Paz García-Portilla; Leticia García-Álvarez; Anna Mané; Clemente Garcia-Rizo; Gisela Sugranyes; Daniel Bergé; Miguel Bernardo; Emilio Fernandez-Egea; Julio Bobes
AIMS To analyse the underlying structure of the negative syndrome of schizophrenia as it is represented in the Brief Negative Symptom Scale. METHODS Cross-sectional, multicentre study, employing data from 190 evaluations. STATISTICS Exploratory factor analysis using the principal component analysis method. RESULTS The three-component solution explained 77.4% of the total variance. Pearson correlation coefficients between components were: 1-2=-0.494, 1-3=-0.117, and 2-3=0.179. CONCLUSION Our solution favours a three-component structure of the negative syndrome, consisting of: external world (anhedonia and asociality), inner world (avolition and blunted affect), and alogia, with the latter only marginally related to the two former components.
Psychiatry Research-neuroimaging | 2015
Anna Mané; Miguel Fernández-Expósito; Daniel Bergé; Laura Gómez-Pérez; Agnés Sabaté; Alba Toll; Laura Diaz; Cristobal Diez-Aja; Víctor Pérez
The mechanism underneath the relationship between cannabis and psychosis remains controversial, for which several hypotheses have been proposed, including cannabis as self-medication and cannabis as a risk for the development of psychosis. The aim of this work was to study the relationship between cannabis and psychosis in first-episode psychosis cannabis users and non-users, and non-psychotic cannabis users. The age at the first psychotic episode, duration of untreated psychosis, psychopathology and reasons for cannabis use were assessed. First-episode psychosis cannabis users showed an earlier age at psychosis onset than non-user patients. No significant differences in symptomatology were found. The distinguishing reasons to use cannabis for patients with first-episode psychosis with respect to non-psychotic users were to arrange their thoughts and deal with hallucinations and suspiciousness. These findings are in agreement with both hypotheses: self-medication and secondary psychosis hypothesis. However, longitudinal prospective cohort studies assessing reasons for cannabis use are needed to investigate both hypotheses and their complementarity.
Schizophrenia Research | 2017
Gisela Mezquida; Bibiana Cabrera; Miquel Bioque; Silvia Amoretti; Antonio Lobo; Ana González-Pinto; Ana Espliego; Iluminada Corripio; Eduard Vieta; Josefina Castro-Fornieles; Daniel Bergé; María J. Escartí; Angela Ibáñez; Rafael Penadés; Ana M. Sánchez-Torres; Miguel Bernardo; Ana Meseguer; Emilio Fernandez-Egea; Jorge Vidal; Mara Parellada; Anna Alonso; Mireia Rabella; Patricia Vega; Amaia Ugarte; Helena Andrés-Bergareche; Fabiola Modrego; Julio Sanjuán; Eduardo J. Aguilar; Antoni Bulbena; Anna Mané
AIMS This study aimed to investigate the course of negative symptoms and its stability over a two-year period following a first-episode schizophrenia (FES) and the possible predictors of higher severity in this symptomatology after this period. METHODS In this longitudinal two-year prospective follow-up study we included 268 patients with a FES, according to DSM-IV. Analysis of variance was conducted in patients who completed the full follow-up to study changes in negative symptoms over three visits. Regression analyses were conducted to show correlates and potential predictors of negative symptoms at two-year follow-up. RESULTS There was a significant effect for time in negative symptomatology, which was less severe at one-year follow-up after a FES and remained stable up to two years (Time 1>Time 2>Time 3); F(2,151)=20.45, p<0.001. Poorer premorbid adjustment (p=0.01) and higher negative symptoms at baseline (p<0.001) made a significant contribution to the changes in the negative symptoms severity at two-years after a FES (R2=0.21, p<0.001). CONCLUSIONS We found a reduction in the negative symptomatology at one-year after a FES. This change remained stable at two-year. Our results suggested that the presence of this symptomatology early in the course of the illness, together with a poorer premorbid adjustment, predict more severe negative symptoms at mid-term outcome.
Psychiatry Research-neuroimaging | 2017
Anna Mané; Daniel Bergé; Maria Jose Penzol; Mara Parellada; Miquel Bioque; Antonio Lobo; Ana González-Pinto; Iluminada Corripio; Bibiana Cabrera; Ana M. Sánchez-Torres; Jerónimo Saiz-Ruiz; Miguel Bernardo
Although an interaction between COMT Val158Met and BDNF Val66Met polymorphisms with cannabis use has been proposed with respect to the risk of psychosis emergence, findings remain inconclusive. The aim of the present study was to evaluate the different possible associations between these polymorphisms and early cannabis use and the age at the first episode of psychosis. The relationship between age at psychosis onset and COMT Val158Met and BDNF Val66Met polymorphisms with early cannabis use as well as those factors associated with early cannabis use were investigated. Among 260 Caucasian first-episode psychosis patients, early cannabis use and the presence of the met-allele from the BDNF Val66Met polymorphism were significantly associated with age at psychosis onset. Furthermore, early cannabis use was significantly associated with male gender in the logistic regression analysis. These findings provide evidence of the important role of early cannabis use and the Val66Met BDNF polymorphism on age at psychosis onset and they point out to sex-specific differences in cannabis use patterns.
PeerJ | 2016
L. Galindo; Francisco Pastoriza; Daniel Bergé; Anna Mané; Marisol Picado; Antonio Bulbena; Patricia Robledo; Víctor Pérez; Oscar Vilarroya; Claude Robert Cloninger
The heritability of schizophrenia and most personality traits has been well established, but the role of personality in susceptibility to schizophrenia remains uncertain. The aim of this study was to test for an association between personality traits and Neurological Soft Signs (NSS), a well-known biological marker of schizophrenia, in non-psychotic relatives of patients with schizophrenia. For this purpose, we evaluated the NSS scale and personality measured by the Temperament and Character inventory (TCI-R) in three groups of subjects: 29 patients with schizophrenia, 24 unaffected relatives and 37 controls. The results showed that patients with schizophrenia were more asocial (higher harm avoidance and lower reward dependence), more perseverative (higher persistence), and more schizotypal (lower self-directedness and cooperativeness, higher self-transcendence). The unaffected relatives showed higher harm avoidance, lower self-directedness and cooperativeness than the healthy controls. Higher NSS scores and sub-scores were found in patients and non-psychotic relatives compared with the controls. Among all the patients, total NSS scores were positively correlated with harm avoidance but negatively correlated with novelty seeking and persistence. Total NSS were also correlated with low scores on self-directedness and cooperativeness, which are indicators of personality disorder. Our results show that susceptibility to NSS and to schizophrenia are both related to individual differences in the temperament and character features in non-psychotic relatives of patients with schizophrenia. High harm avoidance, low persistence, low self-directedness and low cooperativeness contribute to both the risk of NSS and schizophrenia. These findings highlight the value of using both assessments to study high risk populations.
Community Mental Health Journal | 2015
Daniel Bergé; Anna Mané; Francina Fonseca; Alba Toll; Ana Merino; Víctor Pérez; Antoni Bulbena
Abstract This study investigates differences in terms of clinical and treatment management in psychiatric hospitalization associated to smoking ban. We collected data regarding medication, socio-demographic and admission characteristics from all patients admitted to an acute psychiatric hospital before and after a smoking ban was in force. We also assessed a limited sample of patients before and after the ban regarding nicotine dependence, motivation to quit smoking and attitudes towards the ban. More number of leaves of absence and movement restrictions during the ban period occurred in comparison to the pre-ban period. On the contrary a lack of significant differences in terms of hospital stay (duration, rate of voluntary admissions and voluntary discharges), use of sedatives and doses of antipsychotics was found. A period of adjustment regarding the deal with leave of access and facilitate nicotine replacement treatment may help future psychiatric facilities planning smoking free policies.